Structure-Activity Relationship Study of Cannabidiol-Based Analogs As Negative Allosteric Modulators of the μ-Opioid Receptor

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2023 Jul 12

PMID 37437224

Authors

Taryn Bosquez-Berger

Jessica A Gudorf

Charles P Kuntz

Jacob A Desmond

Jonathan P Schlebach

Michael S VanNieuwenhze

Alex Straiker

Affiliations

Soon will be listed here.

Abstract

The US faces an unprecedented surge in fatal drug overdoses. Naloxone, the only antidote for opiate overdose, competes at the mu opioid receptor (μOR) orthosteric site. Naloxone struggles against fentanyl-class synthetic opioids that now cause ∼80% of deaths. Negative allosteric modulators (NAMs) targeting secondary sites may noncompetitively downregulate μOR activation. (-)-Cannabidiol ((-)-CBD) is a candidate μOR NAM. To explore its therapeutic potential, we evaluated the structure-activity relationships among CBD analogs to identify NAMs with increased potency. Using a cyclic AMP assay, we characterize reversal of μOR activation by 15 CBD analogs, several of which proved more potent than (-)-CBD. Comparative docking investigations suggest that potent compounds interact with a putative allosteric pocket to stabilize the inactive μOR conformation. Finally, these compounds enhance naloxone displacement of fentanyl from the orthosteric site. Our results suggest that CBD analogs offer considerable potential for the development of next-generation antidotes for opioid overdose.

Citing Articles

CBD Versus CBDP: Comparing In Vitro Receptor-Binding Activities.

Haghdoost M, Young S, Holloway A, Roberts M, Zvorsky I, Bonn-Miller M Int J Mol Sci. 2024; 25(14).

PMID: 39062976 PMC: 11277192. DOI: 10.3390/ijms25147724.

Advances, opportunities, and challenges in methods for interrogating the structure activity relationships of natural products.

Ancajas C, Oyedele A, Butt C, Walker A Nat Prod Rep. 2024; 41(10):1543-1578.

PMID: 38912779 PMC: 11484176. DOI: 10.1039/d4np00009a.

Cannabidiol at Nanomolar Concentrations Negatively Affects Signaling through the Adenosine A Receptor.

Raich I, Lillo J, Ferreiro-Vera C, Sanchez de Medina V, Navarro G, Franco R Int J Mol Sci. 2023; 24(24).

PMID: 38139329 PMC: 10744210. DOI: 10.3390/ijms242417500.

References

Feng Y, He X, Yang Y, Chao D, Lazarus L, Xia Y . Current research on opioid receptor function. Curr Drug Targets. 2011; 13(2):230-46. PMC: 3371376. DOI: 10.2174/138945012799201612. View

BLUMBERG H, DAYTON H, WOLF P . Counteraction of narcotic antagonist analgesics by the narcotic antagonist Naloxone. Proc Soc Exp Biol Med. 1966; 123(3):755-8. DOI: 10.3181/00379727-123-31595. View

Al-Hasani R, Bruchas M . Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011; 115(6):1363-81. PMC: 3698859. DOI: 10.1097/ALN.0b013e318238bba6. View

Labadie G, Viswanathan R, Poulter C . Farnesyl diphosphate analogues with omega-bioorthogonal azide and alkyne functional groups for protein farnesyl transferase-catalyzed ligation reactions. J Org Chem. 2007; 72(24):9291-7. PMC: 2516946. DOI: 10.1021/jo7017747. View

Anand R, Singh Cham P, Gannedi V, Sharma S, Kumar M, Singh R . Stereoselective Synthesis of Nonpsychotic Natural Cannabidiol and Its Unnatural/Terpenyl/Tail-Modified Analogues. J Org Chem. 2022; 87(7):4489-4498. DOI: 10.1021/acs.joc.1c02571. View

Shultz Z, Lawrence G, Jacobson J, Cruz E, Leahy J . Enantioselective Total Synthesis of Cannabinoids-A Route for Analogue Development. Org Lett. 2018; 20(2):381-384. DOI: 10.1021/acs.orglett.7b03668. View

Kenakin T, Miller L . Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev. 2010; 62(2):265-304. PMC: 2879912. DOI: 10.1124/pr.108.000992. View

Changeux J, Christopoulos A . Allosteric Modulation as a Unifying Mechanism for Receptor Function and Regulation. Cell. 2016; 166(5):1084-1102. DOI: 10.1016/j.cell.2016.08.015. View

Kozela E, Haj C, Hanus L, Chourasia M, Shurki A, Juknat A . HU-446 and HU-465, Derivatives of the Non-psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells. Chem Biol Drug Des. 2015; 87(1):143-53. DOI: 10.1111/cbdd.12637. View

10.

Harada K, Ito M, Wang X, Tanaka M, Wongso D, Konno A . Red fluorescent protein-based cAMP indicator applicable to optogenetics and in vivo imaging. Sci Rep. 2017; 7(1):7351. PMC: 5544736. DOI: 10.1038/s41598-017-07820-6. View

11.

Suzuki J, El-Haddad S . A review: Fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend. 2017; 171:107-116. DOI: 10.1016/j.drugalcdep.2016.11.033. View

12.

Livingston K, Stanczyk M, Burford N, Alt A, Canals M, Traynor J . Pharmacologic Evidence for a Putative Conserved Allosteric Site on Opioid Receptors. Mol Pharmacol. 2017; 93(2):157-167. PMC: 5767684. DOI: 10.1124/mol.117.109561. View

13.

Ravindranath P, Sanner M . AutoSite: an automated approach for pseudo-ligands prediction-from ligand-binding sites identification to predicting key ligand atoms. Bioinformatics. 2016; 32(20):3142-3149. PMC: 5048065. DOI: 10.1093/bioinformatics/btw367. View

14.

Mascal M, Hafezi N, Wang D, Hu Y, Serra G, Dallas M . Synthetic, non-intoxicating 8,9-dihydrocannabidiol for the mitigation of seizures. Sci Rep. 2019; 9(1):7778. PMC: 6533278. DOI: 10.1038/s41598-019-44056-y. View

15.

Peng P, Sandler A . A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology. 1999; 90(2):576-99. DOI: 10.1097/00000542-199902000-00034. View

16.

Kandasamy R, Hillhouse T, Livingston K, Kochan K, Meurice C, Eans S . Positive allosteric modulation of the mu-opioid receptor produces analgesia with reduced side effects. Proc Natl Acad Sci U S A. 2021; 118(16). PMC: 8072371. DOI: 10.1073/pnas.2000017118. View

17.

Pathan H, Williams J . Basic opioid pharmacology: an update. Br J Pain. 2015; 6(1):11-6. PMC: 4590096. DOI: 10.1177/2049463712438493. View

18.

Ibeas Bih C, Chen T, Nunn A, Bazelot M, Dallas M, Whalley B . Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics. 2015; 12(4):699-730. PMC: 4604182. DOI: 10.1007/s13311-015-0377-3. View

19.

Tuyet , Harada , Hashimoto , Hatsuda , Oku . Asymmetric synthesis of axially chiral biaryls via desymmetrization of 2,2',6,6'-tetrahydroxybiphenyl using 1,4-Di-O-benzyl-L-threitol as a chiral template. J Org Chem. 2000; 65(5):1335-43. DOI: 10.1021/jo991364g. View

20.

Golliher A, Tenorio A, Dimauro N, Mairata N, Holguin F, Maio W . Using (+)-Carvone to access novel derivatives of (+)--Cannabidiol: the first asymmetric syntheses of (+)--CBDP and (+)--CBDV. Tetrahedron Lett. 2021; 67. PMC: 8513745. DOI: 10.1016/j.tetlet.2021.152891. View